세계의 제약용 AI 시장

Global Artificial Intelligence in Pharmaceutical Market to Reach US$5.8 Billion by 2030

The global market for Artificial Intelligence in Pharmaceutical estimated at US$1.2 Billion in the year 2024, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 30.1% over the analysis period 2024-2030. AI Hardware, one of the segments analyzed in the report, is expected to record a 31.6% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the AI Software segment is estimated at 27.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$314.5 Million While China is Forecast to Grow at 28.5% CAGR

The Artificial Intelligence in Pharmaceutical market in the U.S. is estimated at US$314.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$873.7 Million by the year 2030 trailing a CAGR of 28.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 27.7% and 25.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 20.8% CAGR.

Global Artificial Intelligence in Pharmaceutical Market - Key Trends & Drivers Summarized

Why Is Artificial Intelligence Becoming a Game-Changer in the Pharmaceutical Industry?

Artificial Intelligence (AI) is rapidly transforming the pharmaceutical industry by reshaping how drugs are discovered, developed, manufactured, and brought to market. As drug development becomes increasingly costly, time-intensive, and data-heavy, AI offers powerful tools to streamline R&D workflows, identify novel drug candidates, and optimize clinical trial design. Traditional pharma models often take over a decade and billions of dollars to bring a single drug to market, with high attrition rates. AI, particularly machine learning (ML) and deep learning, is addressing these inefficiencies by accelerating hit-to-lead identification, predicting compound efficacy and toxicity, and repurposing existing drugs with greater precision and speed.

AI's ability to analyze vast datasets-ranging from omics data and electronic health records to biomedical literature and molecular libraries-enables a more targeted and hypothesis-driven approach to drug discovery. Pharma companies are leveraging AI to uncover hidden relationships between disease mechanisms and therapeutic pathways, drastically reducing the trial-and-error component of early-stage R&D. Additionally, AI is being deployed in commercial operations to personalize physician outreach, optimize pricing strategies, forecast demand, and improve patient adherence. As pharma transitions toward data-centric innovation models, AI is becoming central to competitive advantage and operational agility.

How Are AI-Driven Platforms Accelerating Drug Discovery and Clinical Development?

AI is significantly compressing timelines in drug discovery through predictive modeling, molecular simulations, and automated high-throughput screening. Deep learning algorithms trained on vast compound datasets can predict biological activity, binding affinity, ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties, and off-target effects, allowing researchers to focus on the most promising candidates. Generative AI models are designing entirely new molecular structures with desired properties, while natural language processing (NLP) tools extract actionable insights from scientific literature and clinical trial databases, enriching target validation and hypothesis generation.

In clinical development, AI is transforming trial design and execution. Machine learning models are being used to identify optimal trial sites, predict patient recruitment rates, and select populations most likely to respond to therapy based on genetic or phenotypic data. AI-enabled remote monitoring and real-world data integration are enhancing adaptive trial designs and post-market surveillance, improving both safety assessments and regulatory compliance. These efficiencies not only reduce cost and attrition but also open the door to precision trials that align with personalized medicine paradigms. As AI continues to bridge the gap between discovery and delivery, it is reshaping the pharmaceutical development lifecycle into a faster, more predictive, and patient-centric process.

Where Is Adoption of AI in Pharmaceuticals Accelerating and Which Stakeholders Are Leading the Charge?

AI adoption in the pharmaceutical industry is accelerating across North America, Europe, and Asia-Pacific, with the U.S. leading in terms of investment, partnerships, and AI start-up activity. Global pharma leaders such as Pfizer, Novartis, Roche, AstraZeneca, and Sanofi are actively partnering with AI-first biotech firms and academic institutions to co-develop proprietary algorithms and next-gen drug discovery engines. Major tech players like Google (DeepMind), IBM Watson Health, and NVIDIA are also collaborating with pharma to provide computing infrastructure and AI platforms tailored for biomedical research.

Europe is emerging as a hub for AI-powered pharmaceutical innovation, particularly in the U.K., Germany, and Switzerland, where strong biotech ecosystems and government funding are fueling cross-sector collaboration. Asia-Pacific, led by China and South Korea, is seeing robust growth driven by national AI strategies, population-scale health datasets, and rapidly advancing clinical trial capabilities. Startups specializing in AI for drug discovery, such as BenevolentAI, Insilico Medicine, Recursion, and Atomwise, are gaining traction by offering scalable platforms that integrate cheminformatics, bioinformatics, and predictive analytics. CROs (Contract Research Organizations) and CDMOs (Contract Development and Manufacturing Organizations) are also integrating AI to enhance service offerings across clinical and commercial stages.

What Is Driving the Global Growth of AI in the Pharmaceutical Sector?

The growth in the artificial intelligence in pharmaceutical market is driven by several converging factors, including the escalating cost and complexity of drug development, the explosion of biomedical data, and the shift toward precision medicine. A primary driver is the increasing ability of AI systems to integrate and analyze multidimensional datasets-spanning genomics, proteomics, imaging, EHRs, and market intelligence-to support faster, evidence-based decisions. Regulatory agencies are also showing openness to AI-enabled innovations, with the FDA and EMA providing guidance on real-world data use, algorithm transparency, and digital biomarker validation.

Venture capital investment, M&A activity, and strategic alliances between pharma and AI vendors are accelerating innovation pipelines. The COVID-19 pandemic further validated AI’s role in therapeutic modeling, vaccine development, and epidemiological tracking, reinforcing institutional confidence in AI's scalability and impact. Cloud computing, improved data interoperability, and federated learning models are also reducing the barriers to AI adoption by enabling secure, large-scale model training across global data silos. As AI becomes embedded in end-to-end pharmaceutical operations, a critical strategic question emerges: Can the pharmaceutical industry fully harness AI to shorten development timelines, reduce failure rates, and bring safer, more effective therapies to patients faster than ever before?

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence in Pharmaceutical market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Hardware, Software, Services); Technology (Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method, Other Technologies); Drug Type (Large Molecules, Small Molecules); Application (Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain, Other Applications); End-User (Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

• Absci Corporation
• Anima Biotech
• Antiverse
• Atomwise
• BenevolentAI
• BPGbio
• Cloud Pharmaceuticals
• Deep Genomics
• Exscientia
• Generate Biomedicines
• GNS Healthcare
• Healx
• IBM Watson Health
• Iktos
• Insilico Medicine
• Insitro
• InveniAI
• Isomorphic Labs
• Microsoft Corporation
• Model Medicines

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Artificial Intelligence in Pharmaceutical - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • AI-Driven Drug Discovery Reduces Preclinical Development Timelines Across Therapeutic Areas
  • Machine Learning Enhances Candidate Molecule Screening and Predictive Toxicology in Pharma
  • Clinical Trial Design Optimization Through AI Improves Patient Stratification and Endpoint Selection
  • Integration of AI in Drug Repurposing Unlocks New Revenue Paths for Established Pharma Pipelines
  • Virtual Screening and De Novo Drug Design Tools Accelerate Innovation in Pharma R&D
  • AI-Enhanced Pharmacovigilance Improves Real-Time Detection of Adverse Drug Reactions
  • Regulatory Engagement With AI-Supported Submissions Encourages Broader Pharmaceutical Adoption
  • Natural Language Processing Automates Literature Review and IP Landscape Analysis for Drug Development
  • AI Integration in Manufacturing Quality Control Improves Yield and Reduces Batch Failures
  • Oncology and Rare Disease Drug Pipelines See Early Wins Through AI-Augmented Discovery
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Artificial Intelligence in Pharmaceutical Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Hardware by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Hardware by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Large Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Large Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Clinical Trial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Research & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Research & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Drug Manufacturing & Supply Chain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Drug Manufacturing & Supply Chain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 24: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 25: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World 6-Year Perspective for Hospitals & Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 29: World 6-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 30: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 31: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Natural Language Processing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World 6-Year Perspective for Natural Language Processing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 34: World Recent Past, Current & Future Analysis for Context-aware Processing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 35: World 6-Year Perspective for Context-aware Processing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 36: World Recent Past, Current & Future Analysis for Deep Learning by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 37: World 6-Year Perspective for Deep Learning by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Querying Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World 6-Year Perspective for Querying Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 40: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 41: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 42: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 43: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
  • TABLE 46: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 47: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
  • TABLE 48: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 49: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
• CANADA
  • TABLE 52: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
  • TABLE 54: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
  • TABLE 58: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
  • TABLE 60: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
• JAPAN
  • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
  • TABLE 64: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
  • TABLE 66: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
  • TABLE 70: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
• CHINA
  • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 72: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 73: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
  • TABLE 76: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 77: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
  • TABLE 78: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 79: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
• EUROPE
  • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 82: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 83: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 84: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
  • TABLE 88: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
  • TABLE 90: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
• FRANCE
  • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 94: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 95: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
  • TABLE 96: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 97: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
  • TABLE 100: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 101: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
  • TABLE 102: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 103: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
• GERMANY
  • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
  • TABLE 106: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 107: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
  • TABLE 108: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 109: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
  • TABLE 112: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 113: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
• ITALY
  • TABLE 114: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 115: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
  • TABLE 118: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 119: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
  • TABLE 120: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 121: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
• UNITED KINGDOM
  • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 124: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 125: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
  • TABLE 126: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 127: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
  • TABLE 130: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 131: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
  • TABLE 132: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 133: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
  • TABLE 136: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 137: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
  • TABLE 138: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 139: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
  • TABLE 142: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 143: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
• ASIA-PACIFIC
  • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 144: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 145: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
  • TABLE 148: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 149: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
  • TABLE 150: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 151: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 154: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 155: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
  • TABLE 156: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 157: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
  • TABLE 158: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
  • TABLE 160: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 161: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
  • TABLE 162: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 163: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030

IV. COMPETITION